Search for a trial

Mindfulness Based Cognitive Therapy for subjective fatigue in patients with multiple sclerosis: a prospective cohort study on effectiveness and feasibility.

The purpose of the present study is the evaluation of the effectiveness of MBCT in MS patients. Based on previous research we hypothesize that after the MBCT intervention period, MS patients will have significantly less symptoms of fatigue than…

Randomized, multicenter, double-blind, placebo-controlled, parallel group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

The primary objective of the study is to determine the efficacy of 2 different doses of IgPro20 (0.2 g/kg bw and/or 0.4 g/kg bw) in the maintenance treatment of CIDP in comparison to placeboSecondary objectives:* To investigate the efficacy of…

A randomized double blind, placebo-controlled study of fluoxetine in progressive multiple sclerosis (FLUOX-PMS)

We expect that in people with multiple sclerosis the processing of energy substances such as sugars (energy metabolism)i n the brains is not optimal . In our view this could explain the progressive deterioration of the disease. Currently there are…

Isolation of skin fibroblasts from MS patients for reprogramming into induced pluripotent stem cells

In this study we aim to address the hypothesis that oligodendrocytes and oligodendrocyte precursor cells from MS patients exhibit epigenetically determined differences in protein expression profiles and functional behavior in comparison to those…

Is Transcranial Magnetic Stimulation a potential tool for cognitive therapy in Multiple Sclerosis?

The aim of the proposed pilot study is to explore the efficacy of rTMS in inducing a (transient) localized increase in brain activity of MS patients which is hypothesized to be beneficial for cognitive functioning. This is the first step that needs…

A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

The study is designed to evaluate the efficacy and safety of fingolimod in the treatment of CIDP compared with placebo. Data from this study will be used to support the registration of fingolimod in the indication of CIDP.